Cocrystal Pharma Inc (COCP) Stock Price, Quote & News

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 262 7123

Website: www.cocrystalpharma.com

Address:

19805 North Creek Parkway, Bothell, United States

bulmar Nov. 13 at 7:24 PM

$COCP 🗑️

0 · Reply

xDOUGx Nov. 13 at 6:50 PM

$COCP for you, always in the loading zone…. It's hurts as it drops right? All 100 accounts can't save this stock… I will see my 0.20 cent soon. And you will still be talking about the moon. Negative progressive baby, you can't get me out.

0 · Reply

elon_musk22 Nov. 13 at 4:06 PM

$COCP back to load zone again 🚀

0 · Reply

elon_musk22 Nov. 13 at 4:05 PM

$COCP Rippped from 1.30 to $3.55 90 million shares and it was marvelous to cash out on 125% return too bad you got crushed again on your short LMfaooooo 😂

0 · Reply

xDOUGx Nov. 13 at 4:53 AM

$COCP lol

1 · Reply

elon_musk22 Nov. 11 at 2:49 PM

$COCP next run to $5 sticks than $20 and than $50+++++ big strong data coming 🚨

2 · Reply

elon_musk22 Nov. 11 at 2:44 PM

$COCP everything points to you lost all your money bashing stock it ran to 1.30 to 3.30 September 12th 90 million shares slam dunk you lost all your money on the short 🤡 lmfaoooooooo

0 · Reply

elon_musk22 Nov. 11 at 2:25 PM

$COCP insiders buying at the bottom especially in biotech stock will expode before end of year little bashers melt down is too funny https://www.cocrystalpharma.com/news/press-releases/detail/219/cocrystal-pharma-insiders-purchase-1-03-million-in-private

0 · Reply

elon_musk22 Nov. 11 at 1:59 PM

$COCP small punter alert tic tok 🤡 post your short ticket which doesn't exist moron insiders just purchased $1 million go back to mommy

0 · Reply

xDOUGx Nov. 11 at 12:56 PM

$COCP tick tok tick tok, 0.20 incoming… it will be a fast drop. You have been warned

0 · Reply

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Oct 30, 2025, 8:00 AM EDT - 16 days ago

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 27, 2025, 8:00 AM EDT - 19 days ago

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Oct 2, 2025, 8:00 AM EDT - 6 weeks ago

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Sep 15, 2025, 4:30 PM EDT - 2 months ago

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 9:43 AM EDT - 2 months ago

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Sep 8, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 3, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Aug 14, 2025, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Aug 5, 2025, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Jul 10, 2025, 8:00 AM EDT - 4 months ago

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

May 29, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 28, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 15, 2025, 8:00 AM EDT - 6 months ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Apr 24, 2025, 8:00 AM EDT - 7 months ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 16, 2025, 8:00 AM EDT - 7 months ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Mar 31, 2025, 8:00 AM EDT - 8 months ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 6, 2025, 8:00 AM EST - 9 months ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Dec 31, 2024, 2:21 PM EST - 11 months ago

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31, 2024, 8:00 AM EST - 11 months ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 15, 2024, 3:00 PM EDT - 1 year ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

May 13, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 1, 2024, 8:00 AM EDT - 1 year ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 5, 2024, 8:30 AM EST - 1 year ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Dec 6, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 27, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Apr 10, 2023, 8:30 AM EDT - 2 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Jan 26, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 23, 2023, 9:00 AM EST - 3 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Dec 1, 2022, 4:05 PM EST - 3 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Nov 17, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 1, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Oct 26, 2022, 8:00 AM EDT - 3 years ago

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Oct 5, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 3, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Aug 8, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Aug 3, 2022, 9:00 AM EDT - 3 years ago

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

May 18, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

May 11, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

Apr 19, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

bulmar Nov. 13 at 7:24 PM

$COCP 🗑️

0 · Reply

xDOUGx Nov. 13 at 6:50 PM

0 · Reply

elon_musk22 Nov. 13 at 4:06 PM

$COCP back to load zone again 🚀

0 · Reply

elon_musk22 Nov. 13 at 4:05 PM

$COCP Rippped from 1.30 to $3.55 90 million shares and it was marvelous to cash out on 125% return too bad you got crushed again on your short LMfaooooo 😂

0 · Reply

xDOUGx Nov. 13 at 4:53 AM

$COCP lol

1 · Reply

elon_musk22 Nov. 11 at 2:49 PM

$COCP next run to $5 sticks than $20 and than $50+++++ big strong data coming 🚨

2 · Reply

elon_musk22 Nov. 11 at 2:44 PM

$COCP everything points to you lost all your money bashing stock it ran to 1.30 to 3.30 September 12th 90 million shares slam dunk you lost all your money on the short 🤡 lmfaoooooooo

0 · Reply

elon_musk22 Nov. 11 at 2:25 PM

0 · Reply

elon_musk22 Nov. 11 at 1:59 PM

$COCP small punter alert tic tok 🤡 post your short ticket which doesn't exist moron insiders just purchased $1 million go back to mommy

0 · Reply

xDOUGx Nov. 11 at 12:56 PM

$COCP tick tok tick tok, 0.20 incoming… it will be a fast drop. You have been warned

0 · Reply

Adi198903 Nov. 10 at 2:32 PM

$COCP run

1 · Reply

LA3333 Nov. 7 at 6:06 PM

$COCP flatlining at a $1.. really putting the coc in the cocp …

1 · Reply

xDOUGx Nov. 7 at 4:22 PM

$COCP where is my 100 accounts friend now. You better off shorting this to the grave. Join short club

0 · Reply

inthebay Nov. 6 at 9:57 PM

$COCP Will we get another run here?

1 · Reply

Gstoned Nov. 6 at 7:03 PM

$COCP uh..oh…under $1 followed by huge dilution then r/s. Rinse and repeat 🤣

0 · Reply

Sabby_Management Nov. 5 at 3:19 AM

$COCP Phil Frost my man.

3 · Reply

xDOUGx Nov. 5 at 2:14 AM

$COCP get out while you can

0 · Reply

xDOUGx Nov. 5 at 2:14 AM

$COCP like I said… don't even need to look anymore, waiting for 50 cents now

0 · Reply

bulmar Nov. 4 at 3:09 PM

$COCP Management through presentations and research have failed to get significant institutional investment here. Dilution and reverse splits and the occasional pump and dump rule the day.

0 · Reply

bulmar Nov. 4 at 3:02 PM

$COCP yeah this sucks!

0 · Reply

LA3333 Nov. 3 at 3:21 PM

$COCP you know you’re deep when you’re satisfied to see +.01 over the weekend…

1 · Reply

resurrect_momo21 Oct. 30 at 12:24 PM

$CMBM momo players time to load up at bottom on one of my favs $COCP new big insider buying unheard of at the lows it bolted from 1.50 to almost 4 pre market 85 million shares sept 12th

0 · Reply

Market Cap	10.58M
Revenue (ttm)	0.00
Net Income (ttm)	-17.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	39,000
Avg Vol	1,938,882
Day's Range	N/A - N/A
Shares Out	10.28M
Stochastic %K	22%
Beta	2.24
Analysts	Strong Sell
Price Target	$8.00